The Walden Group is pleased to provide access to its 2024 Year-end Strategic Healthcare M&A Report …
The Walden Group Represented RICA Surgical in its Sale to Mastel Surgical, a Pacific Surgical Company
The Walden Group is pleased to announce that it represented RICA Surgical Products, Inc., as investment banker and M&A adviser, in its sale to Mastel Precision Surgical Instruments, Inc., a member of the Pacific Surgical family of companies (based primarily in Canada).
The Walden Group Releases Q2 2024 Strategic Healthcare M&A Report
The Walden Group is pleased to provide access to its Q2 Strategic Healthcare M&A Report, which includes: Q2 2024 Market Developments Noteworthy M&A Deals By Sector Top Deals > $100m in Transaction Value Announced or Closed in Q2 2024 Performance of Leading Healthcare Companies Analysis of More Than 45 Q2 M&A …
The Walden Group Releases Q1 2024 Strategic Healthcare M&A Report
The Walden Group is pleased to provide access to its Strategic Healthcare M&A Report, which includes: Q1 2024 Market Developments Noteworthy M&A Deals By Sector Top Deals > $100m in Transaction Value Announced or Closed in Q1 2024 Performance of Leading Healthcare Companies Analysis of More Than 45 Q1 M&A Transactions Click …
The Walden Group Releases 2023 Year-End Strategic Healthcare M&A Report
The Walden Group is pleased to provide access to its 2023 Year-end Strategic Healthcare M&A Report …
The Walden Group 2024 Medical Device Outsourcing Report
The Walden Group releases its 2024 Medical Device Outsourcing Developments report.
The Walden Group Releases Q3 2023 Strategic Healthcare M&A Report
The Walden Group is pleased to provide access to its Q3 2023 Strategic Healthcare M&A Report, which includes: Q3 2023 Market Overview Noteworthy M&A Deals By Sector Top Deals > $100m in Transaction Value Announced or Closed in Q3 2023 Performance of Leading Healthcare Companies Analysis of More Than 45 Q3 M&A …
The Walden Group Releases Q2 2023 Strategic Healthcare M&A Report
The Walden Group is pleased to provide access to its Q2 2023 Strategic Healthcare M&A Report, which includes: Q2 2023 Market Overview Noteworthy M&A Deals By Sector Top Deals > $100m in Transaction Value Announced or Closed in Q2 2023 Performance of Leading Healthcare Companies Analysis of More Than 45 Q2 M&A …
The Walden Group Releases Q1 2023 Strategic Healthcare M&A Report
The Walden Group is pleased to provide access to its Q1 2023 Strategic Healthcare M&A Report, which includes: Q1 2023 Market Overview Noteworthy M&A Deals By Sector Top Deals > $100m in Transaction Value Announced or Closed in Q1 2023 Performance of Leading Healthcare Companies Analysis of More Than 45 Q1 M&A …
Werfen Group Buys Immucor for $2b
Spain-based manufacturer and distributor of diagnostic instruments Werfen has acquired Immucor, a manufacturer of transfusion and transplant diagnostic devices. The acquisition adds platelet detection, diagnostic analyzers, blood monitoring and molecular testing products that help match patients and donors. Deal terms — $2b. Keywords: Healthcare Investment Banking, Healthcare M&A, Healthcare Mergers, Medical Devices; Diagnostics